Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. - Wikidata - awgldk - TriplyDB

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

http://www.wikidata.org/entity/Q35849125

about

Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?Mesenchymal stem cells and immunomodulation: current status and future prospects Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus Mesenchymal stem cells: immune evasive, not immune privileged Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens Interactions between MSCs and immune cells: implications for bone healing.Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo?Stem cells and cell therapies in lung biology and lung diseases The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Grou Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice.Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.Immunogenicity of undifferentiated and differentiated allogeneic mouse mesenchymal stem cells.Recipient Glycemic Micro-environments Govern Therapeutic Effects of Mesenchymal Stem Cell Infusion on Osteopenia Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells?Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus.Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis How stem cells speak with host immune cells in inflammatory brain diseases The role of bone marrow mesenchymal stromal cell derivatives in skin wound healing in diabetic mice.Mycoplasma contamination revisited: mesenchymal stromal cells harboring Mycoplasma hyorhinis potently inhibit lymphocyte proliferation in vitro.Advances in progenitor cell therapy using scaffolding constructs for central nervous system injury.Stem cell transplantation for muscular dystrophy: the challenge of immune response.Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.Gimme shelter: the immune system during pregnancy.Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy.Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplant Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins.Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.Clinical implication of allogenic implantation of adipogenic differentiated adipose-derived stem cells.Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials.Mesenchymal stem cells engineered to inhibit complement-mediated damage.

P2860

Q24644691-8EF316F2-4069-4DBD-ADFB-832718E6FFA9 Q26745715-E24FCDDB-B936-4B7F-84CF-2AE0F46B6FC7 Q26750318-09E87935-0358-4C78-AF49-5E5733F3AE2B Q26770191-CF96A3A8-4DA1-4E07-9E10-07EC42C62DB3 Q26775513-FA85D9EB-2462-4400-A7AE-61C94A60F0CF Q26822005-5A687DE9-FDA3-4C35-AA00-29BEA34D313E Q26825272-A46A0C0C-956B-4E5F-BEEE-F252F98548DC Q26853374-BAC9A89D-8383-4AAF-8597-0AA8E7CC8C67 Q26864580-FB9C1C41-9644-4267-B9D7-1F36CEC0D5A5 Q27003371-4FB78FA9-F45C-4EBC-ABA5-0EF12ECE0368 Q27489354-C04F109A-DD6D-4207-BAB8-788EADB51F9D Q28083741-2C884B5E-4082-4FCC-8DB7-05C9F99058A3 Q28084829-DA74CEB9-B7FF-4474-8E93-24CC5F6F4FEC Q30486086-8C2A4F83-289E-4F50-BF33-D87B36ED7F08 Q31143348-5CFCC826-50F8-4B95-B17A-ECACA7C99DA5 Q33505675-1ADF66F2-2F51-4F94-8C27-D4E787C6A8C7 Q33528988-C3CD8816-A958-4911-AA97-5CC9909E3728 Q33582286-42A91903-DBED-48D0-B787-E0F7F72E5A27 Q33588206-58A648D9-BC86-4C57-B12D-6153498B9710 Q33658311-0E6047A8-78F2-49F6-B432-8E072F89DCE9 Q33712984-73E4039F-0EA9-4658-96AC-3917A273F332 Q33719419-DAF8D4AA-53C9-4590-8C9C-46EB97475677 Q33746086-92F5C3E2-6678-4FB7-9B92-41E1D8E74F60 Q33769303-62BCFC76-2039-458E-A0E4-0C2E11F18BC9 Q33776557-A66BB545-62A7-4CAB-80ED-4CA5C432DA40 Q33778239-34FBF428-C9A8-48DD-8D3F-4E2070B69B5F Q33802826-C1FA2DB0-BB2F-4D86-A165-653DCF77DFC8 Q33870573-387D6C6A-D162-44BB-BBCF-15DA54F1F2E1 Q33902416-9783C953-6F63-4552-9011-287F6F339456 Q34097940-3051D905-05B1-4A36-9E83-5678129BB1B1 Q34138063-F6D6EFBF-A1AE-450F-A51C-5EAAFAEEA49C Q34177939-F6109BD5-B457-4784-918A-3D6966DED33A Q34259085-873FECD1-587A-4438-95AB-40C16D9765B8 Q34275442-6C2CB2B9-A26F-4398-B7E5-03990CE441AD Q34278561-B4938AC9-50E5-4FD1-A031-3F4B9AE38FD3 Q34292404-41491194-B022-41A5-9E4E-8251625210E8 Q34400439-9ECE9ED2-CF07-40D2-A148-E68AB768A776 Q34429024-00A99F97-E59A-4D93-B5DB-24E6993DF1FC Q34475694-8546ECC0-3B9A-4386-A9CB-E862BF2F3637 Q34653955-45EC01E7-25EE-4128-8DB7-5F22F0AEADB4

P2860

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

http://www.wikidata.org/entity/Q35849125

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@ast

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@en

type

label

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@ast

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@en

prefLabel

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@ast

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@en

P1433

Q35849125-C57ECFED-3024-466C-A184-8B6818A7FE88

P1476

Q35849125-7DF0BD6C-34F8-441E-BD3A-1C1BEF4886BB

P2093

Q35849125-03D08AE2-2DAB-4058-8818-21764F0B7B87

Q35849125-3E16C172-B990-4A86-BDB3-0C20A0530104

Q35849125-7CDA6E22-CC45-4AA2-8A41-9CDE9A5D3EC1

Q35849125-93BFCD91-F288-44B9-99A2-3832A6E66B64

Q35849125-996D3E8E-CB8F-4E0C-8926-7147BCD9A00B

Q35849125-D76E1C66-CF00-4712-B064-E48A535C1453

P2860

Q35849125-059D600C-0347-48CC-8F60-571DA3B72B69

Q35849125-0D63DA17-79EF-412A-8B73-1B99715BF43D

Q35849125-1E0A86C5-7548-4B2A-ABC7-40881701E2BC

Q35849125-3170137D-AB25-4FCE-8395-6487598FAD35

Q35849125-42A972F0-04F6-472F-B1DE-CD0EF9D9358D

Q35849125-5E12A8A1-E377-4227-92D1-551967078235

Q35849125-675FDF22-BC64-4032-BEAA-19D4DC1F73DD

Q35849125-71250DA0-83F2-447E-8C75-471307C19996

Q35849125-7F66B6B7-5351-4870-8BAA-C5A2027E0B6A

Q35849125-7FFCD2E6-AB8B-4F5B-8002-C4DAF96253AB

P304

Q35849125-35419F73-445F-4F00-9851-D6E239D60B76

P31

Q35849125-43F7FF4C-DD2A-4C99-8F46-A6A21C396498

P356

Q35849125-00B716F8-38A8-44B5-B6C4-8C5E0AF0586E

P407

Q35849125-97B9A53B-0CDF-49C7-910A-E54501A20A6A

P433

Q35849125-C2721A46-7439-41ED-8723-FF93FC31DEB5

P478

Q35849125-044DC785-0E37-4FD9-BFF8-4427CBB200F9

P577

Q35849125-89833F6B-5508-4352-AC8C-DA893ACA69FA

P5875

Q35849125-9BE0F259-E29A-41C8-80A5-0D12E930AD61

P698

Q35849125-6D880A8D-DB75-468B-A679-244B7EDD35D0

P932

Q35849125-EEAFB416-E8ED-4A07-9377-01E493FC3CEA

P356

BLOOD-2005-11-011650

P1433

P1476

Donor-derived mesenchymal stem ...... in a nonmyeloablative setting.

@en

P2093

Alma J Nauta

http://www.w3.org/2001/XMLSchema#string

Alwine B Kruisselbrink

http://www.w3.org/2001/XMLSchema#string

Ellie G A Lurvink

http://www.w3.org/2001/XMLSchema#string

Geert Westerhuis

http://www.w3.org/2001/XMLSchema#string

Roel Willemze

http://www.w3.org/2001/XMLSchema#string

Willem E Fibbe

http://www.w3.org/2001/XMLSchema#string

P2860

Multilineage potential of adult human mesenchymal stem cells

Human mesenchymal stem cells modulate allogeneic immune cell responses

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice.

Mesenchymal stem cells: biology and potential clinical uses.

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.

Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta.

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

P304

2114-2120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-11-011650

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7090365

http://www.w3.org/2001/XMLSchema#string

P698

16690970

http://www.w3.org/2001/XMLSchema#string

P932

1895546

http://www.w3.org/2001/XMLSchema#string